Arca
Skip to content

Hyperhidrosis

Drug research and approvals for hyperhidrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 3 studies of hyperhidrosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.

  • Recruiting worldwide: 3
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 3 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

2 approved, 2 in phase 3, 4 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Sofpironium, Glycopyrronium

Onabotulinumtoxina
Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Oxybutynin
Phase 3 Muscarinic acetylcholine receptor M3 antagonist
Umeclidinium
Phase 2 Muscarinic acetylcholine receptor M3 antagonist
Botulinum toxin type a
Phase 2 Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
Dexmecamylamine
Phase 2 Neuronal acetylcholine receptor; alpha4/beta2 antagonist
Rimabotulinumtoxinb
Phase 2 Vesicle-associated membrane protein 2 inhibitor
Alcohol
Phase 1

How Its Trials Ended

110 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 20 whose ending is known, 55% met their primary endpoint, 0% missed it and 45% stopped early.

  • Completed, result not reported7467%
  • Met its primary endpoint1110%
  • Ongoing87%
  • Status unknown87%
  • Stopped: other or unclear44%
  • Stopped: sponsor or business decision33%
  • Stopped: lack of efficacy11%
  • Stopped: enrollment or feasibility11%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Oct 20, 2015A phase 2a study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied umeclidinium/gsk573719 in subjects with primary…UmeclidiniumGSKClosed
May 1, 2014A phase 2, randomized, double-blind, vehicle controlled, comparator study of the effect of drm04b and drm04 in subjects with axillary hyperhidrosisGlycopyrronium (DRM04) /glycopyrrolateDermira IncorporatedOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.